TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WEAVE™ Trial: Wingspan StEnt System Post MArket SurVEillance Study
Brief Summary: The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.


Options:
A: Arm Label: Wingspan Stent System; Type: OTHER; Interventions: Device: Wingspan Stent System | Intervention Type: DEVICE; Name: Wingspan Stent System; Assigned to Arm(s): Wingspan Stent System
B: Arm Label: intensive medical management plus stenting; Type: EXPERIMENTAL; Interventions: Device: intracranial angioplasty and stenting | Arm Label: intensive medical management alone; Type: EXPERIMENTAL; Interventions: Other: intensive medical management | Intervention Type: DEVICE; Name: intracranial angioplasty and stenting; Assigned to Arm(s): intensive medical management plus stenting | Intervention Type: OTHER; Name: intensive medical management; Assigned to Arm(s): intensive medical management alone
C: Arm Label: Intracranial stenting group; Type: EXPERIMENTAL; Interventions: Procedure: Intracranial stenting group | Arm Label: medical group; Type: ACTIVE_COMPARATOR; Interventions: Drug: medical group | Intervention Type: PROCEDURE; Name: Intracranial stenting group; Assigned to Arm(s): Intracranial stenting group | Intervention Type: DRUG; Name: medical group; Assigned to Arm(s): medical group
D: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)
Brief Summary: This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as mealtime insulin in subjects with type 1 diabetes.


Options:
A: Arm Label: IDeg OD; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin aspart | Arm Label: IGlar OD; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IGlar OD | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): IDeg OD, IGlar OD
B: Arm Label: IDeg OD + IAsp followed by IGlar OD + IAsp; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin glargine, Drug: insulin aspart | Arm Label: IGlar OD + IAsp followed by IDeg OD + IAsp; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin degludec, Drug: insulin glargine, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD + IAsp followed by IGlar OD + IAsp, IGlar OD + IAsp followed by IDeg OD + IAsp | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IDeg OD + IAsp followed by IGlar OD + IAsp, IGlar OD + IAsp followed by IDeg OD + IAsp | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): IDeg OD + IAsp followed by IGlar OD + IAsp, IGlar OD + IAsp followed by IDeg OD + IAsp
C: N/A
D: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): insulin detemir

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 2, 2-STAGE, 2-COHORT STUDY OF TALAZOPARIB (BMN 673) ADMINISTERED TO GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER
Brief Summary: The purpose of this 2-stage, 2-cohort Phase 2 trial is to evaluate the safety and efficacy of talazoparib (also known as BMN 673) in subjects with locally advanced or metastatic breast cancer with a deleterious germline BRCA 1 or BRCA 2 mutation. Subjects will be assigned to either Cohort 1 or 2 based on prior chemotherapy for metastatic disease:

* Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression \> 8 weeks following the last dose of platinum; or
* Cohort 2) Subjects who have received \> 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease


Options:
A: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Physician's choice chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's choice chemotherapy | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Physician's choice chemotherapy; Assigned to Arm(s): Physician's choice chemotherapy
B: Arm Label: Arm G/C; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Arm Label: Arm G/C/I; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine/carboplatin, Drug: iniparib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): Arm G/C, Arm G/C/I | Intervention Type: DRUG; Name: iniparib; Assigned to Arm(s): Arm G/C/I
C: Arm Label: talazoparib; Type: EXPERIMENTAL; Interventions: Drug: talazoparib | Intervention Type: DRUG; Name: talazoparib; Assigned to Arm(s): talazoparib
D: Arm Label: talazoparib; Type: EXPERIMENTAL; Interventions: Drug: talazoparib | Arm Label: Physician's-Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's-Choice | Intervention Type: DRUG; Name: talazoparib; Assigned to Arm(s): talazoparib | Intervention Type: DRUG; Name: Physician's-Choice; Assigned to Arm(s): Physician's-Choice

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Substudy of the NONSEDA Trial (NCT01967680): Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Cognitive Function
Brief Summary: Through many years, the standard care has been to use continuous sedation of critically ill patients during mechanical ventilation. However, preliminary randomised clinical trials indicate that it is beneficial to reduce the sedation level in these patients. The NONSEDA trial is an investigator-initiated, randomised, clinical, parallel-group, multinational, superiority trial designed to include 700 patients from at least six ICUs in Denmark, Norway and Sweden, comparing no sedation with sedation and a daily wake-up trial during mechanical ventilation. This is a substudy of the NONSEDA trial, concerning 250 patients included at trialsite Kolding, Denmark. The aim of the substudy is to assess the effects of no sedation on delirium during admission and cognitive function after discharge from ICU.

Our hypothesis is that critically ill patients who are not sedated during mechanical ventilation will have better cognitive function after discharge.


Options:
A: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
B: Arm Label: Non-sedation; Type: EXPERIMENTAL; Interventions: Other: Non-sedation | Arm Label: Sedation; Type: ACTIVE_COMPARATOR; Interventions: Other: Control: Sedation | Intervention Type: OTHER; Name: Non-sedation; Assigned to Arm(s): Non-sedation | Intervention Type: OTHER; Name: Control: Sedation; Assigned to Arm(s): Sedation
C: Arm Label: delirious patients; Type: N/A; Interventions: N/A | Arm Label: non-delirious patients; Type: N/A; Interventions: N/A
D: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease
Brief Summary: This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pimavanserin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pimavanserin tartrate | Intervention Type: DRUG; Name: Pimavanserin tartrate; Assigned to Arm(s): Pimavanserin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
C: Arm Label: Person-centered Care; Type: EXPERIMENTAL; Interventions: Other: Person-centered Care, Other: Optimised Treatment | Arm Label: Optimised Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimised Treatment | Intervention Type: OTHER; Name: Person-centered Care; Assigned to Arm(s): Person-centered Care | Intervention Type: OTHER; Name: Optimised Treatment; Assigned to Arm(s): Optimised Treatment, Person-centered Care
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Communication, Behavioral: Systematic Pain Assessment and Treatment, Behavioral: Medication Review, Behavioral: Occupational therapy, Behavioral: Safety | Intervention Type: BEHAVIORAL; Name: Communication; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Systematic Pain Assessment and Treatment; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Medication Review; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Occupational therapy; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Safety; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease
Brief Summary: This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Brexpiprazole, OPC-34712 | Arm Label: Brexpiprazole (flexible dose range 0.5 to 2 mg); Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Intervention Type: DRUG; Name: Brexpiprazole, OPC-34712; Assigned to Arm(s): Brexpiprazole (flexible dose range 0.5 to 2 mg), Placebo
B: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pimavanserin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pimavanserin tartrate | Intervention Type: DRUG; Name: Pimavanserin tartrate; Assigned to Arm(s): Pimavanserin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Arm Label: Brexpiprazole 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Arm Label: Brexpiprazole 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Intervention Type: DRUG; Name: Brexpiprazole, OPC-34712; Assigned to Arm(s): Brexpiprazole 1 mg, Brexpiprazole 2 mg | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases.
Brief Summary: This study will evaluate the clinical and pathological response to vemurafenib and cobimetinib in the neoadjuvant treatment of patients with histologically confirmed, BRAF V600 mutation-positive Stage IIIB and C melanoma. 20 patients will be treated with vemurafenib and cobimetinib for 2 months. Then they will be assessed for surgery. Patients will undergo surgery and subsequently resume taking vemurafenib and cobimetinib after recovery from surgery. Patients will undergo radiation therapy if appropriate then continue vemurafenib and cobimetinib. The maximum treatment period is 12 months. After 12 months of treatment, patients will be followed for disease recurrence and survival during for a total of 5 years.


Options:
A: Arm Label: Vemurafenib, pill, twice daily; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib, pill, twice daily | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Vemurafenib, pill, twice daily
B: Arm Label: Dabrafenib and trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Dabrafenib and trametinib placebos; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Dabrafenib and trametinib placebos
C: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ipilimumab | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ipilimumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Integrative Multilevel Study for Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: This study involves development and testing of a patient and family-centered transitional care program for patients who are hospitalized with Chronic Obstructive Pulmonary Disease (COPD) exacerbations. The study intervention includes tailored services to address individual patients' biopsychosocial needs, starting early during hospital stay and continuing for 3 months post hospital discharge.

The study hypothesis is that compared to usual care, the study intervention will : a) Improve patient health- related quality of life and survival, and reduce use of hospital and emergency room visits; b) result in improved patient experience, self- confidence, and self-care behaviors; c) result in improved family caregivers coping skills, self-confidence, and problem solving skills to address patient barriers to care and treatment.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Outreach education training | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: No outreach education training | Intervention Type: BEHAVIORAL; Name: Outreach education training; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: No outreach education training; Assigned to Arm(s): Control
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
C: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: BREATHE program; Type: EXPERIMENTAL; Interventions: Other: BREATHE program | Intervention Type: OTHER; Name: BREATHE program; Assigned to Arm(s): BREATHE program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Integration; Type: EXPERIMENTAL; Interventions: Other: Integration | Arm Label: Co-Location; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integration; Assigned to Arm(s): Integration

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Integrative Multilevel Study for Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: This study involves development and testing of a patient and family-centered transitional care program for patients who are hospitalized with Chronic Obstructive Pulmonary Disease (COPD) exacerbations. The study intervention includes tailored services to address individual patients' biopsychosocial needs, starting early during hospital stay and continuing for 3 months post hospital discharge.

The study hypothesis is that compared to usual care, the study intervention will : a) Improve patient health- related quality of life and survival, and reduce use of hospital and emergency room visits; b) result in improved patient experience, self- confidence, and self-care behaviors; c) result in improved family caregivers coping skills, self-confidence, and problem solving skills to address patient barriers to care and treatment.


Options:
A: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: BREATHE program; Type: EXPERIMENTAL; Interventions: Other: BREATHE program | Intervention Type: OTHER; Name: BREATHE program; Assigned to Arm(s): BREATHE program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Web Platform | Intervention Type: OTHER; Name: Web Platform; Assigned to Arm(s): Intervention group
C: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
D: Arm Label: COPD education + Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: COPD education + Usual care | Arm Label: Physical activity self-management; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity self-management | Intervention Type: BEHAVIORAL; Name: Physical activity self-management; Assigned to Arm(s): Physical activity self-management | Intervention Type: OTHER; Name: COPD education + Usual care; Assigned to Arm(s): COPD education + Usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electronically Connected Health Coaching in Improving Type 2 Diabetes Self Management - Phase III Trial
Brief Summary: Patients with Type 2 Diabetes randomly allocated to the intervention arm (health coaching + smartphone-based health promotion software) will have significantly better Hemoglobin A1c levels at 6 months post-intervention than patients with Type 2 Diabetes allocated to the control arm (health coaching alone).


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive care | Arm Label: Intensive Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive care | Intervention Type: OTHER; Name: Intensive care; Assigned to Arm(s): Intensive Care, Usual Care
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
C: Arm Label: Electronic disease management decision support; Type: OTHER; Interventions: Other: Electronic disease management decision support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic disease management decision support; Assigned to Arm(s): Electronic disease management decision support
D: Arm Label: Lifestyle counseling with smartphones; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling with smartphone | Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling with smartphone; Assigned to Arm(s): Lifestyle counseling with smartphones | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of an Ultrasound Guided Bilateral Transversus Abdominis Plane Block With Dexamethasone and Preperitoneal Instillation of Local Anesthetic With Dexamethasone to a Standard Anesthetic Technique for Analgesic Efficacy and Patient Satisfaction Following a Total Extraperitoneal Bilateral Inguinal Hernia Repair: A Prospective Randomized Single Blinded Study
Brief Summary: Comparison of an ultrasound guided bilateral TAP (transversus abdominis plane) block with dexamethasone and preperitoneal instillation of local anesthetic with dexamethasone under direct visualization will be compared it to a standard anesthetic technique (control) following a TEP (total extraperitoneal) bilateral hernia repair. The investigators are hypothesizing that the bilateral TAP block and preperitoneal instillation of local anesthetics with the addition of dexamethasone are superior in terms of patient satisfaction and post-operative pain control when compared to a standard anesthetic technique (no regional technique).


Options:
A: Arm Label: 8 mg dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo, saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 40 mg dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 40 mg dexamethasone, 8 mg dexamethasone, Placebo, saline
B: Intervention Type: DRUG; Name: intravenous ondansetron; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: MK0869, aprepitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron IV; Assigned to Arm(s): N/A
D: Arm Label: Ultrasound guided bilateral TAP block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transversus abdominis plane block (TAP BLOCK) | Arm Label: Instillation of surgical site with local anesthestic.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Instillation of surgical site with local anesthetic. | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Opioid IV medications (Control) | Intervention Type: PROCEDURE; Name: Transversus abdominis plane block (TAP BLOCK); Assigned to Arm(s): Ultrasound guided bilateral TAP block | Intervention Type: PROCEDURE; Name: Instillation of surgical site with local anesthetic.; Assigned to Arm(s): Instillation of surgical site with local anesthestic. | Intervention Type: PROCEDURE; Name: Opioid IV medications (Control); Assigned to Arm(s): Control Group

Answer: D